華森製藥(002907.SZ):獲注射用阿魏酸鈉藥品補充申請批件
格隆匯12月3日丨華森製藥(002907.SZ)公佈,公司於近日收到重慶市藥監局簽發的注射用阿魏酸鈉的藥品補充申請批件。將注射用阿魏酸鈉生產地址變更為重慶市榮昌區昌州街道板橋路143號,即公司第五期新建GMP生產基地項目(即公司IPO和可轉債募投項目,以下簡稱“五期項目”或“募投項目”)生產車間。
注射用阿魏酸鈉用於缺血性心腦血管病的輔助治療。本次注射用阿魏酸鈉的生產場地轉移至五期項目,標誌着公司已完成主要產品的場地轉移工作,其他部分產品的場地轉移工作也正在進行中。公司五期項目集成了MES、SCADA、DCS等系統,結合大數據、人工智能,並將進行cGMP認證。項目正式投產(預計2020年12月31日前)後,將極大地釋放公司產能,並進一步提升公司產品質量,有利於公司更好地滿足市場需求。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.